Page 43 - CIBEREHD2016-ENG

Most relevant scientific articles
• Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1- 222.
• Nicolle D., Fabre M., Simon-Coma M., Gorse A., Kappler R., Nonell L. et al. Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management. Hepatology. 2016-.
• Escorsell A., Pavel O., Cardenas A., Morillas R., Llop E., Villanueva C. et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology. 2016;63(6):1957-1967.
• Villanueva C., Albillos A., Genesca J., Abraldes J.G., Calleja J.L., Aracil C. et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. Hepatology. 2016;63(1):197-206.
• Shiffman M.L., Rustgi V., Bennett M., Forns X., Asselah T., Planas Vila R. et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin in HCV-infected patients taking concomitant acid-reducing agents. American Journal of Gastroenterology. 2016;111(6):845-851.
Hightlights
In 2016 the Group has seen a leader change, where Dr. Armengol replaced Dr. Planas after his retirement
in June. Dr. C. Armengol is an i3 stabilized Ramon y Cajal researcher at IGTP, that will be leading a multidisciplinary team composed by 2 MD, 3 PhD - including a Miguel Servet researcher- and 1 pre-doc. The clinical and translational research of the group covered complications of cirrhosis, HCV, liver cancer and the involvement of innate immunity in these pathologies. We have obtained 3 competitive grants
(2 FIS ISCIII and 1 MINECO), we have had active projects as PI or co-PI for a total of 1.738.618 EUR (Juan
de la Cierva contract, 2 FIS ISCIII; 1 MTV3; 2 European projects EFSD and Horizon2020). Among these,
the H2020 ChiLTERN project in which C. Armengol is leading one Work Package is focused on improving the clinical management of pediatric patients with liver cancer. Altogether, the activity of our group resulted in 16 publications including a guideline (total IF: 109,688). Furthermore, we have participated in 9 clinical trials and maintained a network of collaborators with 11 different groups of CIBEREHD, CIBERRES and CIBERDEM, allowing our participation in 5 multicentric projects. We have also consolidated our international collaborations and boosted our innovation and transfer activity by registering 1 patent (EP163823365, transference to market under study), and by collaborating with 2 international companies (XenTECH, Lionex). Concerning our educational activity, 2 doctoral thesis were defended in 2016, 2 pre- doctoral and 1 master students are working in our laboratories. Moreover, we particpated in several national and international conferences and organized a Symposium on “Advances in molecular profiling to improve clinical management of the patient with liver cancer” and an international meeting (http://www.siopelbarcelona2016.org/) that has been a complete success doubling the last attendances with more than 150 participants from 21 different countries.
EHD
research Groups 43